Scott Caroen

1.2k total citations
68 papers, 852 citations indexed

About

Scott Caroen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Scott Caroen has authored 68 papers receiving a total of 852 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 26 papers in Molecular Biology and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Scott Caroen's work include Lung Cancer Research Studies (16 papers), Cancer therapeutics and mechanisms (10 papers) and Lung Cancer Treatments and Mutations (10 papers). Scott Caroen is often cited by papers focused on Lung Cancer Research Studies (16 papers), Cancer therapeutics and mechanisms (10 papers) and Lung Cancer Treatments and Mutations (10 papers). Scott Caroen collaborates with scholars based in United States, South Africa and Finland. Scott Caroen's co-authors include Bryan Oronsky, Tony Reid, Arnold L. Oronsky, Michelle Lybeck, Corey A. Carter, Pedro Cabrales, Tony R. Reid, Neil Oronsky, Christopher Parker and Jan Scicinski and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Scott Caroen

66 papers receiving 835 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott Caroen United States 16 340 309 185 160 90 68 852
Bin Qiao China 18 408 1.2× 353 1.1× 90 0.5× 125 0.8× 188 2.1× 36 874
Subhrajit Saha United States 16 493 1.4× 249 0.8× 166 0.9× 161 1.0× 175 1.9× 37 1.1k
Camilla Palumbo Italy 18 440 1.3× 216 0.7× 129 0.7× 139 0.9× 64 0.7× 50 950
Gregory Tudor United Kingdom 19 526 1.5× 328 1.1× 356 1.9× 59 0.4× 152 1.7× 28 1.3k
Roberta Losi Guembarovski Brazil 18 516 1.5× 358 1.2× 108 0.6× 271 1.7× 173 1.9× 74 1.1k
Beverly R. Wuertz United States 14 329 1.0× 495 1.6× 151 0.8× 214 1.3× 215 2.4× 43 935
Nicolas Magné France 14 268 0.8× 135 0.4× 101 0.5× 88 0.6× 172 1.9× 49 826
Miaoqing Zhao China 16 425 1.3× 171 0.6× 101 0.5× 168 1.1× 199 2.2× 75 792
Lijing Zhu China 16 206 0.6× 161 0.5× 70 0.4× 143 0.9× 56 0.6× 49 816

Countries citing papers authored by Scott Caroen

Since Specialization
Citations

This map shows the geographic impact of Scott Caroen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Caroen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Caroen more than expected).

Fields of papers citing papers by Scott Caroen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Caroen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Caroen. The network helps show where Scott Caroen may publish in the future.

Co-authorship network of co-authors of Scott Caroen

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Caroen. A scholar is included among the top collaborators of Scott Caroen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Caroen. Scott Caroen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mao, Li, et al.. (2024). Lost at SCLC: a review of potential platinum sensitizers. Cancer and Metastasis Reviews. 43(4). 1573–1578.
3.
Reid, Tony, Bryan Oronsky, Scott Caroen, et al.. (2023). Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME). Frontiers in Immunology. 14. 1104753–1104753. 14 indexed citations
4.
Oronsky, Bryan, Lori H. Takahashi, Richard D. Gordon, et al.. (2023). RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist. Frontiers in Oncology. 13. 1204143–1204143. 14 indexed citations
5.
Kesari, Santosh, et al.. (2023). Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient. SHILAP Revista de lepidopterología. 16(1). 178–182. 4 indexed citations
6.
Oronsky, Bryan, et al.. (2023). Data Management 101 for drug developers: A peek behind the curtain. Clinical and Translational Science. 16(9). 1497–1509. 1 indexed citations
7.
Oronsky, Bryan, et al.. (2022). RRx-001 and the “Right stuff”: Protection and treatment in outer space. Life Sciences in Space Research. 35. 69–75. 10 indexed citations
8.
Oronsky, Bryan, Scott Caroen, Michelle Lybeck, et al.. (2022). A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC). Journal of Cancer. 13(9). 2945–2953. 38 indexed citations
9.
Oronsky, Bryan, Tony R. Reid, Christopher Larson, et al.. (2019). REPLATINUM Phase III Randomized Study: RRx-001 + Platinum Doublet Versus Platinum Doublet in Third-Line Small Cell Lung Cancer. Future Oncology. 15(30). 3427–3433. 47 indexed citations
10.
Oronsky, Bryan, et al.. (2018). A note on improved statistical approaches to account for pseudoprogression. Cancer Chemotherapy and Pharmacology. 81(3). 621–626. 4 indexed citations
11.
Brzezniak, Christina, Bryan Oronsky, Jane B. Trepel, et al.. (2017). RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor. Case Reports in Oncology. 10(1). 276–280. 6 indexed citations
12.
Oronsky, Bryan, Scott Caroen, Arnold L. Oronsky, et al.. (2017). Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemotherapy and Pharmacology. 80(5). 895–907. 72 indexed citations
13.
Brzezniak, Christina, Mary Quinn, Bryan Oronsky, et al.. (2017). P2.06-031 QUADRUPLE THREAT: A Pilot Phase 2 Study of RRx-001 in Advanced Lung Cancer Prior to Re-Administration of Platinum Doublets. Journal of Thoracic Oncology. 12(1). S1090–S1091. 1 indexed citations
14.
Carter, Corey A., Bryan Oronsky, Scott Caroen, et al.. (2016). Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets. Case Reports in Oncology. 9(2). 285–289. 8 indexed citations
15.
Carter, Corey A., Paul Peterson, Mary Quinn, et al.. (2016). Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Reports in Oncology. 9(1). 164–170. 12 indexed citations
16.
Kim, Michelle M., Hemant Parmar, Yue Cao, et al.. (2016). Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial. Translational Oncology. 9(2). 108–113. 27 indexed citations
17.
Carter, Corey A., Bryan Oronsky, Jan Scicinski, et al.. (2015). Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor. Case Reports in Oncology. 8(3). 461–465. 11 indexed citations
18.
Carter, Corey A., Scott Caroen, Arnold L. Oronsky, & Bryan Oronsky. (2015). Dysphonia after Bevacizumab Rechallenge: A Case Report. Case Reports in Oncology. 8(3). 423–425. 7 indexed citations
19.
Oronsky, Bryan, Corey A. Carter, Tony R. Reid, et al.. (2015). Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance. Neoplasia. 17(9). 716–722. 18 indexed citations
20.
Oronsky, Bryan, Neil Oronsky, Gary R. Fanger, et al.. (2014). Follow the ATP: Tumor Energy Production: A Perspective. Anti-Cancer Agents in Medicinal Chemistry. 14(9). 1187–1198. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bin Qiao Breakdown of academic impact, for papers by Subhrajit Saha Breakdown of academic impact, for papers by Camilla Palumbo Breakdown of academic impact, for papers by Gregory Tudor Breakdown of academic impact, for papers by Roberta Losi Guembarovski Breakdown of academic impact, for papers by Beverly R. Wuertz Breakdown of academic impact, for papers by Nicolas Magné Breakdown of academic impact, for papers by Miaoqing Zhao Breakdown of academic impact, for papers by Lijing Zhu
Rankless by CCL
2026